Anixa Biosciences Inc (NASDAQ:ANIX) Stock Has Consensus Target Price of $8.00

Shares of Anixa Biosciences Inc (NASDAQ:ANIX) have been given an average rating of “Hold” by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $8.00.

A number of equities research analysts have commented on ANIX shares. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a report on Tuesday, October 6th. Weiss Ratings upgraded Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, September 17th. D. Boral Capital restated a “buy” rating and issued a $10.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Zacks Research lowered Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 19th. Finally, HC Wainwright dropped their price objective on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research note on Tuesday, September 22nd.

Insider Transactions at Anixa Biosciences

In other Anixa Biosciences news, Director Lewis Titterton, Jr. bought 49,036 shares of the firm’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were bought at an average price of $2.69 per share, with a total value of $131,906.84. Following the purchase, the director owned 1,046,003 shares of the company’s stock, valued at $2,813,748.07. This trade represents a 4.92% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders purchased 100,724 shares of company stock worth $286,620. 26.40% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. BlackRock Inc. purchased a new stake in Anixa Biosciences during the 2nd quarter valued at approximately $559,000. GSA Capital Partners LLP bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $329,000. Bank of New York Mellon Corp bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $133,000. Corient Private Wealth LP bought a new stake in shares of Anixa Biosciences during the second quarter valued at approximately $105,000. Finally, Kestra Advisory Services LLC lifted its holdings in shares of Anixa Biosciences by 96.2% in the first quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock worth $132,000 after buying an additional 25,000 shares in the last quarter. 29.13% of the stock is owned by hedge funds and other institutional investors.

Anixa Biosciences Price Performance

Shares of ANIX stock opened at $2.71 on Thursday. The company has a market capitalization of $94.20 million, a price-to-earnings ratio of -8.47 and a beta of 0.47. Anixa Biosciences has a one year low of $2.32 and a one year high of $5.46. The company’s fifty day moving average price is $3.01 and its 200-day moving average price is $2.98.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Wednesday, September 9th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08). Equities research analysts expect that Anixa Biosciences will post -0.31 earnings per share for the current fiscal year.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic.